MetaVia's chief medical officer argues that combination therapies targeting multiple metabolic pathways, not stronger single GLP-1 drugs, will define the next era of obesity treatment. The case rests on three 2026 abstracts: a Phase 1 study of the oxyntomodulin analogue DA-1726 and preclinical…
MetaVia's chief medical officer argues that the next generation of obesity treatment will be defined by combination therapies targeting multiple metabolic pathways, not by stronger single GLP-1 drugs alone. The argument was carried by three abstracts presented at the American Diabetes Association ADA Scientific Sessions and published in 2026 in Diabetes , volume 75, Supplement 1. Together they pair one clinical dataset, a Phase 1 higher-dose cohort study of the oxyntomodulin analogue DA-1726, with two preclinical studies of the G protein-coupled receptor 119 agonist vanoglipel combined with metformin or resmetirom.
The company is using that evidence to shift the debate. Obesity, in MetaVia's framing, is a complex metabolic disorder that frequently coexists with type 2 diabetes, MASH metabolic dysfunction-associated steatohepatitis , cardiovascular disease, and other chronic conditions, and substantial weight loss does not necessarily normalize every aspect of metabolic health. If that premise holds, the next advance will come less from pushing a single receptor harder than from engaging multiple metabolic pathways at once, with the goal of changing outcomes that the scale alone does not capture.
The claim carries a timeline. MetaVia predicts that over the next five years obesity treatment will become increasingly personalized. For a market that has grown extraordinarily over the past several years, driven largely by GLP-1 receptor agonists, that is a strategic statement as much as a forecast: the drugs that defined the current wave will be complemented, not replaced, by what comes next.
All three abstracts were published in 2026 in Diabetes , volume 75, Supplement 1, cited as 75 Supplement 1 . Abstract 3102-LB, authored by W.C. Fang, reports the DA-1726 Phase 1 higher-dose cohort study, an assessment of the oxyntomodulin analogue in humans. Abstract 3043-LB, authored by Y. Chae, describes vanoglipel combined with resmetirom in a diet-induced obese, biopsy-confirmed mouse model of MASH. Abstract 2856-LB, also authored by Y. Chae, describes vanoglipel combined with metformin in a diet-induced obese mouse model.
The endpoints named across the three studies are standard for their stages but revealing in their range:
As a set, those endpoints describe a program that expects an obesity drug to also show something in glycemic regulation and something in the liver. That is the metabolic health agenda made concrete in measurement choices.
The combination strategy is visible in the choice of partners. Vanoglipel is being evaluated with metformin, the first-line therapy for type 2 diabetes, and with resmetirom, a drug developed for MASH. Both are among the most common comorbidities of obesity, and both pairings position vanoglipel not as a standalone therapy but as a component of regimens matched to a patient's metabolic profile.
The DA-1726 Phase 1 higher-dose cohort study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in humans. No efficacy data were described in the abstract, and a Phase 1 design is not equipped to show whether the compound produces durable weight loss or meaningful changes in glucose control or liver measures. What it can establish is exposure, dose tolerance, and a safety signal adequate to advance the program. That is genuinely useful information, but it is limited information.
The two vanoglipel studies are entirely preclinical. The metformin combination was tested in a diet-induced obese mouse model; the resmetirom combination was tested in a diet-induced obese, biopsy-confirmed mouse model of MASH. Diet-induced obesity models reproduce some features of human metabolic disease, including weight gain, insulin resistance, and hepatic steatosis, and biopsy confirmation of MASH strengthens the relevance of the liver study. But the mouse is not a complete model of human obesity, and the translatability of any combination effect must be confirmed in clinical testing.
Neither abstract states sample sizes, study duration, or statistical details. That means the reader can evaluate the direction of the claims but not their magnitude or certainty. The design can support proof-of-mechanism arguments: that adding a GPR119 agonist to metformin or resmetirom produces effects beyond the partner drug alone, in mice. It cannot support dosing, sequencing, or benefit claims in patients. Human data for vanoglipel combinations have not yet been reported, and that is the gap that will decide whether this approach succeeds.
The scientific case rests on complementarity. GLP-1 receptor agonists act through incretin signaling, enhancing glucose-stimulated insulin secretion, slowing gastric emptying, and reducing appetite and food intake. They have produced substantial weight loss in a large portion of patients, but not in all, and the metabolic improvements they deliver do not fully cover the organ systems affected by obesity.
DA-1726 is an oxyntomodulin analogue. Oxyntomodulin is an endogenous peptide that activates both the GLP-1 receptor and the glucagon receptor, so DA-1726 is a single molecule with activity at two pathways. That places it in one of the two forms of combination therapy MetaVia describes: single-molecule multi-pathway agents, where one peptide engages several receptors, and separate drug combinations, where two or more products are given together.
Vanoglipel belongs to the second category. As a G protein-coupled receptor 119 agonist, it targets GPR119, a receptor expressed on pancreatic islets and gut enteroendocrine cells. GPR119 activation promotes glucose-dependent insulin secretion and incretin release, a mechanism thought to improve glycemic control with a lower risk of hypoglycemia than directly forcing insulin output. Paired with metformin, which reduces hepatic glucose production and improves insulin sensitivity, the two drugs attack glucose regulation through different nodes. Paired with resmetirom, a thyroid hormone receptor beta agonist that reduces hepatic fat, the combination targets the liver at the same time as the GPR119 agonist addresses islet and gut signaling.
The hope, stated plainly by MetaVia, is that pairing therapies with complementary mechanisms may produce additive or synergistic effects across multiple clinical outcomes. That is a testable hypothesis, and it is the right hypothesis to test. But synergy must be demonstrated rather than assumed, and the history of combination therapy in other disease areas is full of combinations that were additive in theory and indifferent in practice.
MetaVia's timeline is specific: within the next five years, obesity treatment will become increasingly personalized. The personalization it describes would be organized around four inputs: metabolic profile, comorbidities, treatment goals, and disease stage. A patient with obesity and MASH would be managed differently from a patient with obesity and type 2 diabetes, and both differently from a patient whose primary goal is preserving lean mass during weight reduction.
That framing is a deliberate departure from the current market logic. Over the past several years, the obesity therapeutics market has grown extraordinarily, driven largely by GLP-1 receptor agonists. That growth was built on a single mechanism, applied at increasing doses and with increasing potency. MetaVia's argument is that the next phase will be organized differently: by mechanism combinations selected for the individual rather than by ever-stronger versions of one drug.
The company is explicit that this is an expansion, not a replacement. GLP-1 therapies will be complemented rather than replaced by next-generation combination treatments. That matters for clinicians who have built treatment pathways around GLP-1 drugs and for patients who have benefited from them. It also concedes the weak points of the current generation: not every patient responds equally to GLP-1 therapy, and the drugs carry tolerability problems that limit their use.
For peptide researchers, the clearest signal is that drug design will increasingly be judged on outcomes beyond weight loss. The endpoints now in view, drawn from the program's open questions and its preclinical targets, include insulin sensitivity, lean mass preservation, liver fat reduction, and cardiovascular health. Each of those outcomes places different demands on a peptide: a compound that preserves lean tissue during caloric deficit has different receptor pharmacology from one that simply suppresses appetite, and a compound intended to reduce liver fat may need to reach adequate concentrations in the liver.
The single-molecule multi-pathway approach illustrated by DA-1726, an oxyntomodulin analogue, is attractive to peptide chemists because it packages multiple activities into one synthetic molecule. The separate-drug approach illustrated by vanoglipel's combinations raises different questions: formulation compatibility, dosing schedules, and whether the combination is best delivered as two products or co-formulated into one. For the peptide supply chain, that distinction is consequential, because co-formulation of a peptide with a small molecule such as metformin or resmetirom introduces entirely new stability, compatibility, and manufacturing considerations.
For clinicians, the implication is that therapeutic choice will become more complicated before it becomes more precise. They will need to match therapy to comorbidity, to stage of disease, and to patient goals, using combinations whose individual components are approved but whose joint effects are only beginning to be studied. That places a premium on clinical trials that measure body composition, liver histology, and glycemic outcomes rather than weight alone.
The evidence base for the combination argument is thin, and the company does not pretend otherwise. The argument is made by MetaVia's chief medical officer, with a disclosure that MetaVia is the company of which they are chief medical officer. The supporting evidence is primarily preclinical, drawn from mouse models. The only clinical study cited is the single Phase 1 study of DA-1726. No sample sizes, effect sizes, or statistical details are provided. This is a strategy document for a development program, not a demonstration that the strategy works.
The unresolved problems are specific. Tolerability issues and weight regain after stopping treatment remain unresolved for the current generation of GLP-1 therapies, and combinations may improve efficacy without solving either problem. Whether combination therapies can preserve lean body mass during weight reduction is unknown. Whether they can reduce liver fat and inflammation at the same time as achieving weight loss is unknown. And the hardest scientific question is one MetaVia poses itself: how can a second mechanism be proven to change disease beyond the number on the scale?
Answering that question will require studies designed around metabolic measurements, not just kilograms lost. Which combinations will be optimized for weight reduction versus glucose control, liver health, or lean mass preservation remains an open question, and the answer will determine whether the next five years of obesity treatment look like MetaVia predicts: personalized, multi-pathway, and built on peptide drugs that do more than move the scale.
Peptides referenced: Glucagon, GLP-1.
Related reading: Employers Drop GLP-1 Weight-Loss Coverage as Costs Climb and Use Rises, Energean shares slide 12.3% in 2026 while Brent holds above $92, Seoul seizes 4,155 illegal Wegovy and Mounjaro imports in six months, Updated review ranks tirzepatide top among GLP-1 weight-loss agents.